Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.

CONCLUSION: The HERmione study showed that, in a real-life setting, the safety of SC trastuzumab administered in HER2-positive eBC patients is consistent with data reported from previous clinical trials, without new safety concerns or QoL deterioration. PMID: 31670262 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31670262?dopt=Abstract

Source: Breast - October 17, 2019 Category: Cancer & Oncology Authors: Jacquin JP, Uwer L, Savignoni A, Ferrero JM, Lortholary A, Solub D, Delaporte F, Chalabi N, Pibre S, Belkacemi Y Tags: Breast Source Type: research